Shots:
- J&J reported P-III (MARIPOSA) trial data assessing Rybrevant + Lazcluze vs osimertinib or Lazcluze alone as a 1L treatment of locally advanced or metastatic NSCLC pts (n=1074) with EGFR ex19del or L858R substitution mutations
- At 37.8mos. mFU, trial showed superior OS, with mOS not reached vs 36.7mos. for osimertinib-treated pts, plus 56% vs 44% pts were alive at 3.5yrs. Projections suggest Rybrevant + Lazcluze could extend mOS by at least 12mos.; data to be shared with global health authorities & presented at ELCC 2025
- Trial also showed improvements in other 2EPs, incl. intracranial PFS, DoR, & ORR, with prolonged time to symptomatic progression (TTSP) by over 14mos. vs osimertinib (43.6 vs 29.3mos.)
Ref: J&J | Image: J&J
Related News:- Johnson & Johnson Reports the US FDA’s Approval of Subcutaneous & Intravenous Tremfya for Active Crohn’s Disease (CD)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
